As Chinese drugmakers churn out a record number of novel therapies, industry experts urge an overhaul of pricing, insurance and medical infrastructure to ensure new treatments reach patients
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Caixin hosts a panel discussion on innovative drug R&D at the 2026 Summer Davos on June 23, 2026 in Dalian, Liaoning. Photo: Zhou Xinda/Caixin
Despite efforts to ease pressure on state-run healthcare, commercial insurers covered just 7.8% of the country’s innovative drug…
‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.
With more drugs in clinical trials than any other country, Chinese drugmakers are now shifting focus to the high-risk,…
The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
